Dizal Pharmaceutical Hits Day Low of CNY 50.70 Amid Price Pressure

Dizal (Jiangsu) Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.56% on March 11, 2026. The stock reached an intraday low of CNY 50.70, reflecting a challenging market environment for the company. In terms of performance metrics, Dizal's one-day performance contrasts sharply with the China Shanghai Composite, which saw a modest increase of 0.25%. Over the past week, however, Dizal has shown some resilience, gaining 6.56%, although its one-month performance remains negative at -7.29%. The company's financial health is under scrutiny, highlighted by a low Return on Capital Employed (ROCE) of 18.72%, indicating limited profitability relative to its capital. Additionally, Dizal's high debt-to-equity ratio raises concerns about its long-term growth prospects, especially given its reported losses and negative Return on Equity (ROE) of -62.14%. Overall, the stock's performance today underscores the ongoing challenges faced by Dizal in a competitive market landscape.